Immunohistochemistry Markers Explained

No single stain proves mesothelioma. Pathologists use a panel. Some markers, such as calretinin, WT-1 and CK5/6, are commonly positive in mesothelioma. Others are usually positive in adenocarcinoma and negative in mesothelioma. By running both groups, the pathologist looks for a consistent picture. A result where the mesothelioma markers light up and the adenocarcinoma markers stay quiet supports the diagnosis. Mixed or weak results call for more stains or expert review. This is why reports list several markers rather than one, and why each result is read in context. No marker is perfect, which is why the overall pattern carries more weight than any single result.

Some tests help separate cancer from benign, irritated lining, which can look very similar. Loss of the BAP1 protein in the tumor cells is one example that supports a mesothelioma diagnosis. Another test looks for a specific gene deletion. These markers are especially useful when the tissue sample is small or when the cells look only mildly abnormal. Not every lab runs them routinely. If your report mentions uncertainty between a reactive process and cancer, it is reasonable to ask whether these additional tests were done or could be added.

The stain results usually appear in a section called immunohistochemistry or special studies. Each marker is listed with a result such as positive, negative, focal or diffuse. The pathologist then writes a final diagnosis that sums up the findings. You do not need to interpret each marker yourself. What helps is knowing that the section exists, checking that several markers were tested, and asking your oncologist to walk you through how the results support the diagnosis. Specialist pathologists can re-read the same slides and sometimes add stains without a new biopsy.

1. 1

   Find the immunohistochemistry section in your pathology report and note which markers were tested.

2. 2

   Ask your oncologist to explain how the marker pattern supports your specific diagnosis.

3. 3

   If the report mentions uncertainty, ask whether BAP1 or similar additional tests were performed.

4. 4

   Keep the full report, not just the summary, for second opinions and future records.